A consortium led by Asia healthcare-focused private equity firm CBC Group has agreed to acquire a 46.9% interest in Hugel, a South Korean manufacturer of botox and other health-related pharmaceuticals, for KRW1.7 trillion ($1.5 billion).
Abano Healthcare, a New Zealand dentistry chain owned by BGH Capital and Ontario Teachers’ Pension Plan (OTPP), has agreed to acquire Australian peer 1300 Smiles for an enterprise valuation of A$165 million ($120 million).
Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, has raised $700 million in Series C funding featuring Temasek Holdings, Loyal Valley Capital, and Lilly Asia Ventures.
Inspiration Capital Partners, a China-focused private equity firm established by investment professionals from Vivo Capital and Goldman Sachs, has reached a first close of approximately $65 million on its debut US dollar-denominated fund.
Shukun, a Chinese developer of artificial intelligence (AI) technology used in medical imaging diagnosis, has raised RMB700 million ($108 million) from Goldman Sachs, Primavera Capital Group, Sequoia Capital China, Marathon Venture Partners, and Sage...
MediTrust Health, China-based healthcare payments and insurance platform, has raised RMB2 billion ($309 million) in Series C funding led by Boyu Capital and Janchor Partners.
Baring Private Equity Asia has agreed to buy a healthcare services unit of Anglo-Indian conglomerate Hinduja Group at an enterprise valuation of $1.2 billion.
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB1.5 billion ($231 million) in Series F funding featuring Sequoia Capital China.
Affinity Equity Partners has agreed to sell MedicalDirector, an Australia-based clinic management software developer, to Telstra Health for an enterprise valuation of A$350 million ($257 million).
Joinn Biologics, a China-based contract development and manufacturing organization (CDMO), has raised $150 million in Series B funding led by CPE.
China Merchants Capital has led a $99.5 million funding round for Berry Oncology Corporation, an early cancer screening spin-out from China-based genetic testing specialist Berry Genomics.
GGV Capital has led a $100 million Series A round for BioMap, a China-based biological computing platform. It marks the first time the company has sought external funding.
Vitalbridge Capital, a China-based venture capital firm that spun out from Trustbridge Partners, has achieved a first close of $200 million on its second US dollar-denominated fund.
Sequoia Capital China had led a $100 million Series B round for Bota Biosciences, a China-based biotech company that has developed a next-generation platform for manufacturing high-performing industrial compounds.
Direct secondaries specialist NewQuest Capital Partners has acquired a minority stake in Cloudnine, an India-based hospital chain, by committing primary capital and taking out several existing investors.
TransThera, a China-based drug developer, has raised $100 million in Series D funding led by CPE and China Structural Reform Fund.
PAG has acquired a controlling stake in Acme Formulation Private, an India-based contract development and manufacturing organization (CDMO), for approximately $145 million.
Chinese next-generation sequencing (NGS) player Geneplus Technology has raised a RMB750 million ($116 million) Series C round led by China Construction Bank’s venture unit CCB International.
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
LeapFrong Investments and Khosla Ventures have led a $75 million Series C round for HealthifyMe, a mobile health and fitness app operator with a presence in India and Southeast Asia.
Beauty and wellness are at the vanguard of China’s fast-rising services sector. Investors see clear paths to growth, but size presents a plethora of problems in terms of standardizing service quality
China’s Meiwei Dental Group has raised a RMB1 billion ($150 million) Series B round from Fortune Capital, TFTR Investment, and local conglomerate New Hope Group.
Sherpa Healthcare Partners has led a $30 million Series A for Paq Therapeutics, a Chinese-founded biotech company specializing in treatments based on molecules that enhance the degradation of disease-causing entities.
Silicon Valley-based NewView Capital has led a A$30 million ($22.4 million) Series B round for Australia telehealth platform Eucalyptus.